| Literature DB >> 28827602 |
Weihua Wu1, Tanmoy Dutta1, Arul M Varman1, Aymerick Eudes2, Bianca Manalansan2, Dominique Loqué2, Seema Singh3,4,5.
Abstract
Naturally, many aerobic organisms degrade lignin-derived aromatics through conserved intermediates including protocatechuate and catechol. Employing this microbial approach offers a potential solution for valorizing lignin into valuable chemicals for a potential lignocellulosic biorefinery and enabling bioeconomy. In this study, two hybrid biochemical routes combining lignin chemical depolymerization, plant metabolic engineering, and synthetic pathway reconstruction were demonstrated for valorizing lignin into value-added products. In the biochemical route 1, alkali lignin was chemically depolymerized into vanillin and syringate as major products, which were further bio-converted into cis, cis-muconic acid (ccMA) and pyrogallol, respectively, using engineered Escherichia coli strains. In the second biochemical route, the shikimate pathway of Tobacco plant was engineered to accumulate protocatechuate (PCA) as a soluble intermediate compound. The PCA extracted from the engineered Tobacco was further converted into ccMA using the engineered E. coli strain. This study reports a direct process for converting lignin into ccMA and pyrogallol as value-added chemicals, and more importantly demonstrates benign methods for valorization of polymeric lignin that is inherently heterogeneous and recalcitrant. Our approach also validates the promising combination of plant engineering with microbial chassis development for the production of value added and speciality chemicals.Entities:
Year: 2017 PMID: 28827602 PMCID: PMC5566326 DOI: 10.1038/s41598-017-07895-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Two hybrid biochemical routes of lignin valorization. (A) Ligninolytic pathway of SYK-6. (B) The biochemical route 1 integrated the chemical catalysis and biological funneling the lignin into the ccMA and pyrogallol. While the biochemical route 2 combined the lignin biosynthesis engineering in plant Tobacco to accumulate PCA as intermediate compound and the bioconversion of PCA into ccMA through a synthetic chassis. The pathway in the dark green is shared by both routes. (C) The market values of some of the products made from muconic acid and pyrogallol.
Genes used in this study.
| Gene | Accession Number | Amino Acids | Function | Source |
|---|---|---|---|---|
|
| BAH20873 | 502 | Protocatechuate decarboxylase |
|
|
| BAK67175 | 462 | Syringate O-demethylase |
|
|
| Lp_2945 | 491 | Gallate decarboxylase |
|
|
| BAK65381.1 | 480 | Vanillin dehydrogenase |
|
|
| BAK65949.1 | 471 | 3-O-methylgallate-O-demethylase |
|
|
| BAA07037 | 311 | Catechol 1,2-dioxygenase |
|
|
| GAM30370 | 306 | Catechol 1,2-dioxygenase |
|
|
| YP_001137362.1 | 618 | 3-dehydroshikimate dehydratase |
|
Figure 2GC spectrum of the components of refined lignin treated by hydrogen peroxide oxidation.
Figure 3Bioconversion of vanillin into cis,cis-Muconic acid. (A) synthetic constructs for the bioconversion of vanillin into ccMA. Both constructs harbor four pathway genes:LigV, LigM, AroY, CatA(CatAac or CatApmt2), while construct 2 expressed two copies of AroY. Strains VMY-CatA contains construct 1 with CatA genes from different sources, represented as VMY-CatAac or VMY-CatApmt2; Two strains containing construct 2 were cultured, represented as VMY-YCatAac 1,2 or VMY-YCatpmt2-1,2, respectively; (B) ccMA concentrations from the fermentation broth of strains containg two different constructs; (C) Catechol concentrations from the fermentation broth of strains containg two different constructs; (D) ccMA concentrations of strains containg two different constructs in whole cell bioconversion.
Figure 4Bioconversion of syringate into pyrogallol. (A) Synthetic pathway for the bioconversion of syringate into pyrogallol; (B) pyrogallol and gallic acid concentration without the presence of tetrahydrofolate in the fermentation broth; (C) pyrogallol and gallic acid concentration with the addition of 100 µM tetrahydrofolate in the fermentation broth; (D) pyrogallol and gallic acid concentration in the whole cell bioconversion mixture.
Figure 5Bioconversion of extracted protocatechuate into cis, cis-muconic acid. (A) Synthetic pathway for the bioconversion of PCA into ccMA. Two pathway genes AroY and CatA were co-expressed under same promoter in the plasmid pBbE7K; (B) ccMA concentrations in the fermentation broth; (C) Catechol concentrations in the fermentation broth; (D) catechol concentration in the whole cell bioconversion mixture.
Primers used in this study.
| pBbE7k-AroY-F | 5-TCA |
|---|---|
| pBbE7k-AroY-R | 5- GGATCC |
| pBbE7k-CatAac-F | 5-ATTTCA |
| pBbE7k-CatAac-R | 5-AGATCT |
| pBbE7k-CatApmt2-F | 5-GAATTC |
| pBbE7k-CatApmt2-R | 5-CTCGAG |
| pBbE1a-ColE1-Amp_G-F1 | 5-GGA TCC AAA CTC GAG TAA GGA TCT CCA GGC-3 |
| pBbE1a-ColE1-Amp_G-R1 | 5- CAT TCG ATG GTG TCG ACG TCA GGT GGC ACT-3 |
| pBbE1a-LacI-ptrc-LacO-G-F2 | 5-AGT GCC ACC TGA CGT CGA CAC CAT CGA ATG-3 |
| pBbE1a-LacI-ptrc-LacO-G-R2 | 5-GAA TTC TGA AAT TGT TAT CCG CTC ACA ATT CCA CAC-3 |
| pBbE1a-LigV-Gib-F | 5- GTG TGG AAT TGT GAG CGG ATA ACA ATT TCAGAATTC CCA TAG CCC AAC ATA GAA TAA GGT AC-3 |
| pBbE1a-LigV-Gib-R | 5-CTC CTT GCT TTA ATG GTG GGA AAG AGATCT TTA AAT CGG AAA ATG GCCCGG TTG G-3 |
| pBbE1a-LigM-Gib-F | 5-GAATTC AGATCTCTTTCCCACCATTAAAGCAAGGAGTAAATAATTA ATG AGC GCT CCG ACC AAC CTG-3 |
| pBbE1a-LigM-Gib-R | 5-CGG TGG TAG TCC TTA AAT GAA ATG GT GGATCC TTA CGC GGT CAC CGC CGC TTT A-3 |
| pBbE1a-AroYA-Gib-F | 5-CTCGAG GGATCC ACCATTTCATTTAAGGACTACCACCGCAAC ATG ACA GCC CCT ATT CAA GAC -3 |
| pBbE1a-AroYA-Gib-R | 5- GTT TTA TTT GAT GCC TGG AGA TCC TTA CTCGAG TTA TTT AGC GGA GCC TTG ATT TTT T-3 |
| pBbE1a-DesA-GibF | 5-GTG TGG AAT TGT GAG CGG ATA ACA ATT TCAGAATTC AAGTTTACCCCCTAATTTCAAAGTCGGTTCTTCT ATG GCA AAA TCT CTT CAG GAC G-3 |
| pBbE1a-DesA-GibR | 5-CTC CTT GCT TTA ATG GTG GGA AAG AGATCT TTA GGC TTT TTT CGT CCG CCA G-3 |
| pBbE1a-LigM-GibF | 5-TAA AGATCTC TTTCCCACCATTAAAGCAAGGAGTAAATAATTA ATG AGC GCT CCG ACC AAC CTG-3 |
| pBbE1a-LigM-GibR | 5- CTT cgt tct act tac ttc ccc ttg ata gat agg gc GGATCC TTA CGC GGT CAC CGC CGC TTT AC-3 |
| pBbE1a-LpdC-GibF | 5-GGATCC GCCCTATCTATCAAGGGGAAGTAAGTAGAACGAAG ATG GCG GAA CAG CCT TGG GAC C-3 |
| pBbE1a-Lpdc-GibR | 5-GAT GCC TGG AGA TCC TTA CTC GAG CTCGAG TTA TTT CAG GTA TTT TTC CCA ATC CGC AAC-3 |
| DsRed-F | 5-tcgagctcggtacccggGATACATGAGAATTAAGGGAGTC-3 |
| DsRed-R | 5′-agaagcttggtacccggGAGCTTGCATGCCGGTCGATC-3 |
Strains utilized in this study.
| Strains | Plasmids contained | Pathway genes | construct |
|---|---|---|---|
| VMY-YCatAac | pBbE1a-VMY, pBbE7k-aroY-CatAac |
| 2 |
| VMY-CatAac | pBbE1a-VMY, pBbE7k-CatAac |
| 1 |
| VMY-YCatApmt2 | pBbE1a-VMY, pBbE7k-aroY-CatApmt2 |
| 2 |
| VMY-CatApmt2 | pBbE1a-VMY, pBbE7k-CatApmt2 |
| 1 |
| AroY-CatAac | pBbE7k-AroY-CatAac |
| 4 |
| AroY-CatApmt2 | pBbE7k-AroY-CatApmt2 |
| 4 |
| AML | pBbE1a-AML |
| 3 |
| CV3101 | pTKan- |
| in this study |